Sobi buys Arthrosi to expand gout treatment pipeline

Swedish Orphan Biovitrum (Sobi) has signed an statement for the acquisition of US-based biotechnology institution Arthrosi Therapeutics, a determination that volition grow Sobi’s beingness successful the gout attraction market.

Sobi volition acquisition for Arthrosi Skr9.1bn ($950m) successful cash.

Additional payments of up to Skr5.3bn ($550m) whitethorn beryllium made based connected clinical, regulatory and income milestones.

The acquisition volition supply entree to a next-generation urate transporter 1 (URAT1) inhibitor, pozdeutinurad, presently being assessed successful 2 Phase III trials for the imaginable absorption of progressive and tophaceous gout.

The planetary trials are investigating the imaginable usage of pozdeutinurad, with results anticipated successful 2026.

Arthrosi is processing the therapy, designed to little levels of serum urate, trim gout flares and code tophi [deposits of monosodium urate crystals] successful patients with progressive forms of the disease.

ApicHope holds the rights to the therapy successful Greater China.

The completion of the transaction is contingent connected customary closing conditions, and expected successful the archetypal fractional of 2026.

Arthrosi Therapeutics CEO and laminitis Litain Yeh stated: “We are thrilled to articulation forces with Sobi and look guardant to moving unneurotic to guarantee a seamless modulation arsenic they beforehand pozdeutinurad towards pivotal information and imaginable regulatory filings.

“We judge that Sobi’s planetary expertise successful commercialisation volition accelerate our shared ngo to present pozdeutinurad’s perchance transformative benefits for individuals surviving with gout.”

Sobi intends to concern the upfront outgo chiefly via debt, utilising existing recognition facilities and a caller recognition installation from Handelsbanken and Danske Bank.

The acquisition is anticipated to person a affirmative interaction connected its mid to semipermanent maturation and borderline profile.

Barclays Bank is serving arsenic Sobi’s fiscal advisor for this transaction, and McDermott, Will & Schulte is its ineligible advisor.

"Sobi buys Arthrosi to grow gout attraction pipeline" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.